Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Kent Osborne

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Physiology

Living Beings

Anatomy

Cultured Tumor Cells

Concepts & Ideas

Disease-Free Survival

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Hershman Dawn L; Unger Joseph M; Barlow William E; Hutchins Laura F; Martino Silvana; Osborne C Kent; Livingston Robert B; Albain Kathy S
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.
Strecker Tracy E; Shen Qiang; Zhang Yun; Hill Jamal L; Li Yuxin; Wang Chunyu; Kim Hee-Tae; Gilmer Tona M; Sexton Krystal R; Hilsenbeck Susan G; Osborne C Kent; Brown Powel H
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Creighton Chad J; Massarweh Suleiman; Huang Shixia; Tsimelzon Anna; Hilsenbeck Susan G; Osborne C Kent; Shou Jiang; Malorni Luca; Schiff Rachel
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kent Osborne (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Hershman Dawn L; Unger Joseph M; Barlow William E; Hutchins Laura F; Martino Silvana; Osborne C Kent; Livingston Robert B; Albain Kathy S
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2157-62.
2009: Strecker Tracy E; Shen Qiang; Zhang Yun; Hill Jamal L; Li Yuxin; Wang Chunyu; Kim Hee-Tae; Gilmer Tona M; Sexton Krystal R; Hilsenbeck Susan G; Osborne C Kent; Brown Powel H
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Journal of the National Cancer Institute 2009;101(2):107-13.
2008: Creighton Chad J; Massarweh Suleiman; Huang Shixia; Tsimelzon Anna; Hilsenbeck Susan G; Osborne C Kent; Shou Jiang; Malorni Luca; Schiff Rachel
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Cancer research 2008;68(18):7493-501.
2008: Creighton Chad J; Casa Angelo; Lazard ZaWaunyka; Huang Shixia; Tsimelzon Anna; Hilsenbeck Susan G; Osborne Charles Kent; Lee Adrian V
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4078-85.
2008: Li Xiaoxian; Lewis Michael T; Huang Jian; Gutierrez Carolina; Osborne C Kent; Wu Meng-Fen; Hilsenbeck Susan G; Pavlick Anne; Zhang Xiaomei; Chamness Gary C; Wong Helen; Rosen Jeffrey; Chang Jenny C
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Journal of the National Cancer Institute 2008;100(9):672-9.
2008: Arpino Grazia; Wiechmann Lisa; Osborne C Kent; Schiff Rachel
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Endocrine reviews 2008;29(2):217-33.
2008: Chang Jenny C; Makris Andreas; Gutierrez M Carolina; Hilsenbeck Susan G; Hackett James R; Jeong Jennie; Liu Mei-Lan; Baker Joffre; Clark-Langone Kim; Baehner Frederick L; Sexton Krsytal; Mohsin Syed; Gray Tara; Alvarez Laura; Chamness Gary C; Osborne C Kent; Shak Steven
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
Breast cancer research and treatment 2008;108(2):233-40.
2008: Massarweh Suleiman; Osborne C Kent; Creighton Chad J; Qin Lanfang; Tsimelzon Anna; Huang Shixia; Weiss Heidi; Rimawi Mothaffar; Schiff Rachel
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Cancer research 2008;68(3):826-33.
2007: Friedman Lois C; Romero Catherine; Elledge Richard; Chang Jenny; Kalidas Mamta; Dulay Mario F; Lynch Garrett R; Osborne C Kent
Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancer.
Journal of behavioral medicine 2007;30(4):351-7.
2007: Arpino Grazia; Gutierrez Carolina; Weiss Heidi; Rimawi Mothaffar; Massarweh Suleiman; Bharwani Lavina; De Placido Sabino; Osborne C Kent; Schiff Rachel
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Journal of the National Cancer Institute 2007;99(9):694-705.
2007: Pandya Kishan J; Hu Ping; Osborne C Kent; Falkson Geoffrey; Tormey Douglass C;
Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
American journal of clinical oncology 2007;30(2):113-25.
2007: Linden Hannah M; Haskell Charles M; Green Stephanie J; Osborne C Kent; Sledge George W; Shapiro Charles L; Ingle James N; Lew Danika; Hutchins Laura F; Livingston Robert B; Martino Silvana
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):656-61.
2006: Wang Li Hua; Yang Xiao Yi; Zhang Xiaohu; An Ping; Kim Han-Jong; Huang Jiaqiang; Clarke Robert; Osborne C Kent; Inman John K; Appella Ettore; Farrar William L
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
Cancer cell 2006;10(6):487-99.
2006: Ma Xiao-Jun; Hilsenbeck Susan G; Wang Wilson; Ding Li; Sgroi Dennis C; Bender Richard A; Osborne C Kent; Allred D Craig; Erlander Mark G
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4611-9.
2006: Massarweh Suleiman; Osborne C Kent; Jiang Shou; Wakeling Alan E; Rimawi Mothaffar; Mohsin Syed K; Hilsenbeck Susan; Schiff Rachel
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Cancer research 2006;66(16):8266-73.
2006: Divisova Jana; Kuiatse Isere; Lazard ZaWaunyka; Weiss Heidi; Vreeland Franzanne; Hadsell Darryl L; Schiff Rachel; Osborne C Kent; Lee Adrian V
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Breast cancer research and treatment 2006;98(3):315-27.
2006: Hilsenbeck Susan G; Osborne C Kent
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):1049s-1055s.
2006: Cleator Susan; Tsimelzon Anna; Ashworth Alan; Dowsett Mitch; Dexter Timothy; Powles Trevor; Hilsenbeck Susan; Wong Helen; Osborne C Kent; O'Connell Peter; Chang Jenny C
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
Breast cancer research and treatment 2006;95(3):229-33.
2006: Jiang Shiming; Meyer Rene; Kang Kaiyan; Osborne C Kent; Wong Jiemin; Oesterreich Steffi
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
Molecular endocrinology (Baltimore, Md.) 2006;20(2):311-20.
2006: Martin Michelle D; Hilsenbeck Susan G; Mohsin Syed K; Hopp Torsten A; Clark Gary M; Osborne C Kent; Allred D Craig; O'Connell Peter
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.
Breast cancer research and treatment 2006;95(1):7-12.
2005: Mohsin Syed K; Allred D Craig; Osborne C Kent; Cruz Anatolio; Otto Pamela; Chew Helen; Clark Gary M; Elledge Richard M
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
Breast cancer research and treatment 2005;94(3):205-11.
2005: Tham Yee-Lu; Gomez L Fernando; Mohsin Syed; Gutierrez M Carolina; Weiss Heidi; Hilsenbeck Susan G; Elledge Richard M; Chamness Gary C; Osborne C Kent; Allred D Craig; Chang Jenny C
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
Breast cancer research and treatment 2005;94(3):279-84.
2005: Osborne C Kent; Schiff Rachel; Arpino Grazia; Lee Adrian Susan; Hilsenbeck V G
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Breast (Edinburgh, Scotland) 2005;14(6):458-65.
2005: Hutchins Laura F; Green Stephanie J; Ravdin Peter M; Lew Danika; Martino Silvana; Abeloff Martin; Lyss Alan P; Allred Craig; Rivkin Saul E; Osborne C Kent
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8313-21.
2005: Schiff Rachel; Massarweh Suleiman A; Shou Jiang; Bharwani Lavina; Arpino Grazia; Rimawi Mothaffar; Osborne C Kent
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Cancer chemotherapy and pharmacology 2005;56 Suppl 1():10-20.
2005: Cui Xiaojiang; Schiff Rachel; Arpino Grazia; Osborne C Kent; Lee Adrian V
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7721-35.
2005: Arpino Grazia; Weiss Heidi; Lee Adrian V; Schiff Rachel; De Placido Sabino; Osborne C Kent; Elledge Richard M
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Journal of the National Cancer Institute 2005;97(17):1254-61.
2005: Davidson Nancy E; O'Neill Anne M; Vukov Allen M; Osborne C Kent; Martino Silvana; White Douglas R; Abeloff Martin D
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5973-82.
2005: Dowsett M; Johnston S; Martin L-A; Salter J; Hills M; Detre S; Gutierrez M C; Mohsin S K; Shou J; Allred D C; Schiff R; Osborne C K; Smith I
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Endocrine-related cancer 2005;12 Suppl 1():S113-7.
2005: Howell Anthony; Pippen John; Elledge Richard M; Mauriac Louis; Vergote Ignace; Jones Stephen E; Come Steven E; Osborne C Kent; Robertson John F R
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Cancer 2005;104(2):236-9.
2005: Arpino G; Weiss H L; Clark G M; Hilsenbeck S G; Osborne C K
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4687-94.
2005: Osborne C Kent; Schiff Rachel
Aromatase inhibitors: future directions.
The Journal of steroid biochemistry and molecular biology 2005;95(1-5):183-7.
2005: Gutierrez M Carolina; Detre Simone; Johnston Stephen; Mohsin Syed K; Shou Jiang; Allred D Craig; Schiff Rachel; Osborne C Kent; Dowsett Mitch
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2469-76.
2005: Nabha Sanaa M; Glaros Selina; Hong Meng; Lykkesfeldt Anne E; Schiff Rachel; Osborne Kent; Reddy Kaladhar B
Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.
Oncogene 2005;24(19):3166-76.
2005: Mohsin Syed K; Weiss Heidi L; Gutierrez M Carolina; Chamness Gary C; Schiff Rachel; Digiovanna Michael P; Wang Chun-Xia; Hilsenbeck Susan G; Osborne C Kent; Allred D Craig; Elledge Richard; Chang Jenny C
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2460-8.
2005: Lippman Marc E; Benz Chris; Chinnaiyan Arul; Flockhart David; Harris Adrian; Hudis Clifford; Osborne C Kent; Press Michael F; Rae James; Sledge George W; Van't Veer Laura; Wicha Max
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.
Breast cancer research and treatment 2005;90(1):1-3.
2005: Osborne C Kent; Schiff Rachel
Estrogen-receptor biology: continuing progress and therapeutic implications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(8):1616-22.
2005: Chang Jenny C; Wooten Eric C; Tsimelzon Anna; Hilsenbeck Susan G; Gutierrez M Carolina; Tham Yee-Lu; Kalidas Mamta; Elledge Richard; Mohsin Syed; Osborne C Kent; Chamness Gary C; Allred D Craig; Lewis Michael T; Wong Helen; O'Connell Peter
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1169-77.
2005: Fuqua Suzanne A W; Cui Yukun; Lee Adrian V; Osborne C Kent; Horwitz Kathryn B
Insights into the role of progesterone receptors in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):931-2; author reply 932-3.
2005: Osborne C Kent; Shou Jiang; Massarweh Suleiman; Schiff Rachel
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):865s-70s.
2005: Come Steven E; Buzdar Aman U; Ingle James N; Arteaga Carlos L; Brodie Angela M; Colditz Graham A; Johnston Stephen R D; Kristensen Vessela N; Lønning Per E; McDonnell Donald P; Osborne C Kent; Russo Jose; Santen Richard J; Yee Douglas; Hart Carol S
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):861s-4s.
2005: Pierce Lori J; Hutchins Laura F; Green Stephanie R; Lew Danika L; Gralow Julie R; Livingston Robert B; Osborne C Kent; Albain Kathy S
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):24-9.
2005: Schiff Rachel; Osborne C Kent
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
Breast cancer research : BCR 2005;7(5):205-11.
2004: Hopp Torsten A; Weiss Heidi L; Parra Irma S; Cui Yukun; Osborne C Kent; Fuqua Suzanne A W
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7490-9.
2004: Arpino Grazia; Green Stephanie J; Allred D Craig; Lew Dannika; Martino Silvana; Osborne C Kent; Elledge Richard M
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5670-6.
2004: Shou Jiang; Massarweh Suleiman; Osborne C Kent; Wakeling Alan E; Ali Simale; Weiss Heidi; Schiff Rachel
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Journal of the National Cancer Institute 2004;96(12):926-35.
2004: Howell Anthony; Robertson John F R; Abram Paul; Lichinitser Mikhail R; Elledge Richard; Bajetta Emilio; Watanabe Toru; Morris Charles; Webster Alan; Dimery Isaiah; Osborne C Kent
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1605-13.
2004: Osborne C K; Wakeling A; Nicholson R I
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
British journal of cancer 2004;90 Suppl 1():S2-6.
2004: Schiff Rachel; Massarweh Suleiman A; Shou Jiang; Bharwani Lavina; Mohsin Syed K; Osborne C Kent
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 2):331S-6S.
2004: Howell Anthony; Osborne C Kent; Mauriac Louis
Spreading the word, but not too thinly.
Lancet 2004;363(9403):165-6.
2004: Robertson John F R; Erikstein Bjorn; Osborne Kent C; Pippen John; Come Steven E; Parker Leroy M; Gertler Stan; Harrison Mike P; Clarke David A
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
Clinical pharmacokinetics 2004;43(8):529-38.
2003: Lu Chunhua; Speers Corey; Zhang Yun; Xu Xiaochun; Hill Jamal; Steinbis Emily; Celestino Joseph; Shen Qiang; Kim Heetae; Hilsenbeck Susan; Mohsin Syed K; Wakeling Alan; Osborne C Kent; Brown Powel H
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Journal of the National Cancer Institute 2003;95(24):1825-33.
2003: Osborne C Kent; Schiff Rachel
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
Breast (Edinburgh, Scotland) 2003;12(6):362-7.
2003: Osborne C Kent; Arteaga Carlos L
Role of molecular and genetic markers in breast cancer treatment decisions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23 Suppl):285s-287s.
2003: Chang Jenny C; Wooten Eric C; Tsimelzon Anna; Hilsenbeck Susan G; Gutierrez M Carolina; Elledge Richard; Mohsin Syed; Osborne C Kent; Chamness Gary C; Allred D Craig; O'Connell Peter
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Lancet 2003;362(9381):362-9.
2003: Morrison Ashby J; Herrera Rafael E; Heinsohn Ester Coronado; Schiff Rachel; Osborne C Kent
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
Molecular endocrinology (Baltimore, Md.) 2003;17(8):1543-54.
2003: Robertson John F R; Osborne C Kent; Howell Anthony; Jones Stephen E; Mauriac Louis; Ellis Matthew; Kleeberg Ulrich R; Come Steven E; Vergote Ignace; Gertler Stan; Buzdar Aman; Webster Alan; Morris Charles
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Cancer 2003;98(2):229-38.
2003: Tallman Martin S; Gray Robert; Robert Nicholas J; LeMaistre Charles F; Osborne C Kent; Vaughan William P; Gradishar William J; Pisansky Thomas M; Fetting John; Paietta Elisabeth; Lazarus Hillard M
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
The New England journal of medicine 2003;349(1):17-26.
2003: Mauriac L; Pippen J E; Quaresma Albano J; Gertler S Z; Osborne C K
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
European journal of cancer (Oxford, England : 1990) 2003;39(9):1228-33.
2003: Vergote I; Robertson J F R; Kleeberg U; Burton G; Osborne C K; Mauriac L;
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Breast cancer research and treatment 2003;79(2):207-11.
2003: Fuqua Suzanne A W; Schiff Rachel; Parra Irma; Moore John T; Mohsin Syed K; Osborne C Kent; Clark Gary M; Allred D Craig
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.
Cancer research 2003;63(10):2434-9.
2003: Bardou Valerie-Jeanne; Arpino Grazia; Elledge Richard M; Osborne C Kent; Clark Gary M
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1973-9.
2003: Esteva Francisco J; Glaspy John; Baidas Said; Laufman Leslie; Hutchins Laura; Dickler Maura; Tripathy Debu; Cohen Roger; DeMichele Angela; Yocum Richard C; Osborne C Kent; Hayes Daniel F; Hortobagyi Gabriel N; Winer Eric; Demetri George D
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):999-1006.
2003: Osborne C Kent; Bardou Valerie; Hopp Torsten A; Chamness Gary C; Hilsenbeck Susan G; Fuqua Suzanne A W; Wong Jiemin; Allred D Craig; Clark Gary M; Schiff Rachel
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Journal of the National Cancer Institute 2003;95(5):353-61.
2003: Schiff Rachel; Massarweh Suleiman; Shou Jiang; Osborne C Kent
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):447S-54S.
2003: Come Steven E; Buzdar Aman U; Arteaga Carlos L; Brodie Angela M; Davidson Nancy E; Dowsett Mitch; Ingle James N; Johnston Stephen R D; Lee Adrian V; Osborne C Kent; Pritchard Kathleen I; Vogel Victor G; Winer Eric P; Hart Carol S
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):443S-6S.
2003: Rivkin Saul E; Green Stephanie J; Lew Danika; Costanzi John J; Athens John W; Osborne C Kent; Vaughn Clarence B; Martino Silvana
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Cancer 2003;97(1):21-9.
2002: Lu Huanzhang; Zhang Yufeng; Roberts David D; Osborne C Kent; Templeton Nancy Smyth
Enhanced gene expression in breast cancer cells in vitro and tumors in vivo.
Molecular therapy : the journal of the American Society of Gene Therapy 2002;6(6):783-92.
2002: Liu Yongmin; Ludes-Meyers John; Zhang Yun; Munoz-Medellin Debbie; Kim Hee-Tae; Lu Chunhua; Ge Gouqing; Schiff Rachel; Hilsenbeck Susan G; Osborne C Kent; Brown Powel H
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
Oncogene 2002;21(50):7680-9.
2002: Osborne C K; Pippen J; Jones S E; Parker L M; Ellis M; Come S; Gertler S Z; May J T; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3386-95.
2001: Osborne C K; Schiff R; Fuqua S A; Shou J
Estrogen receptor: current understanding of its activation and modulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
2001: Buzdar A U; Come S E; Brodie A; Ellis M; Goss P E; Ingle J N; Johnston S R; Lee A V; Osborne C K; Vogel V G; Hart C S
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
2001: Oesterreich S; Zhang P; Guler R L; Sun X; Curran E M; Welshons W V; Osborne C K; Lee A V
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.
Cancer research 2001;61(15):5771-7.
2001: Zhao H H; Herrera R E; Coronado-Heinsohn E; Yang M C; Ludes-Meyers J H; Seybold-Tilson K J; Nawaz Z; Yee D; Barr F G; Diab S G; Brown P H; Fuqua S A; Osborne C K
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions.
The Journal of biological chemistry 2001;276(30):27907-12.
2001: Martin M D; Fischbach K; Osborne C K; Mohsin S K; Allred D C; O'Connell P
Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene.
Cancer research 2001;61(9):3578-80.
2001: Hartsough M T; Clare S E; Mair M; Elkahloun A G; Sgroi D; Osborne C K; Clark G; Steeg P S
Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
Cancer research 2001;61(5):2320-7.
2001: Oesterreich S; Allredl D C; Mohsin S K; Zhang Q; Wong H; Lee A V; Osborne C K; O'Connell P
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer.
British journal of cancer 2001;84(4):493-8.
2000: Schiff R; Reddy P; Ahotupa M; Coronado-Heinsohn E; Grim M; Hilsenbeck S G; Lawrence R; Deneke S; Herrera R; Chamness G C; Fuqua S A; Brown P H; Osborne C K
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
Journal of the National Cancer Institute 2000;92(23):1926-34.
2000: Townson S M; Sullivan T; Zhang Q; Clark G M; Osborne C K; Lee A V; Oesterreich S
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3788-96.
2000: Osborne C K; Zhao H; Fuqua S A
Selective estrogen receptor modulators: structure, function, and clinical use.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3172-86.
2000: Howell A; Osborne C K; Morris C; Wakeling A E
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
Cancer 2000;89(4):817-25.
2000: Elledge R M; Green S; Pugh R; Allred D C; Clark G M; Hill J; Ravdin P; Martino S; Osborne C K
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
International journal of cancer. Journal international du cancer 2000;89(2):111-7.
2000: Oesterreich S; Zhang Q; Hopp T; Fuqua S A; Michaelis M; Zhao H H; Davie J R; Osborne C K; Lee A V
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
Molecular endocrinology (Baltimore, Md.) 2000;14(3):369-81.
2000: Chang J; Powles T J; Allred D C; Ashley S E; Makris A; Gregory R K; Osborne C K; Dowsett M
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):616-21.
1999: Chang J; Powles T J; Allred D C; Ashley S E; Clark G M; Makris A; Assersohn L; Gregory R K; Osborne C K; Dowsett M
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3058-63.
1999: Jatoi I; Hilsenbeck S G; Clark G M; Osborne C K
Significance of axillary lymph node metastasis in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2334-40.
1999: O'Connell P; Fischbach K; Hilsenbeck S; Mohsin S K; Fuqua S A; Clark G M; Osborne C K; Allred D C
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.
Journal of the National Cancer Institute 1999;91(16):1391-7.
1999: Osborne C K
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Endocrine-related cancer 1999;6(2):271-6.
1999: Harvey J M; Clark G M; Osborne C K; Allred D C
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1474-81.
1999: Diab S G; Clark G M; Osborne C K; Libby A; Allred D C; Elledge R M
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1442-8.
1999: Lee A V; Jackson J G; Gooch J L; Hilsenbeck S G; Coronado-Heinsohn E; Osborne C K; Yee D
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.
Molecular endocrinology (Baltimore, Md.) 1999;13(5):787-96.
1999: Li S; Chen P L; Subramanian T; Chinnadurai G; Tomlinson G; Osborne C K; Sharp Z D; Lee W H
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage.
The Journal of biological chemistry 1999;274(16):11334-8.
1999: Hilsenbeck S G; Friedrichs W E; Schiff R; O'Connell P; Hansen R K; Osborne C K; Fuqua S A
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.
Journal of the National Cancer Institute 1999;91(5):453-9.
1998: Osborne C K
Tamoxifen in the treatment of breast cancer.
The New England journal of medicine 1998;339(22):1609-18.
1998: Mansour E G; Gray R; Shatila A H; Tormey D C; Cooper M R; Osborne C K; Falkson G
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3486-92.
1998: Geyer C E; Green S J; Moinpour C M; O'Sullivan J; Goodwin D K; Canfield V A; Meyers F J; Osborne C K; Martino S
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
Breast cancer research and treatment 1998;51(2):169-81.
1998: Fetting J H; Gray R; Fairclough D L; Smith T J; Margolin K A; Citron M L; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson I C; Osborne C K; Abeloff M D
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2382-91.
1998: Ciocca D R; Green S; Elledge R M; Clark G M; Pugh R; Ravdin P; Lew D; Martino S; Osborne C K
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1263-6.
1998: Falkson G; Gelman R S; Pandya K J; Osborne C K; Tormey D; Cummings F J; Sledge G W; Abeloff M D
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1669-76.
1998: Diab S G; Hilsenbeck S G; de Moor C; Clark G M; Osborne C K; Ravdin P M; Elledge R M
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1655-60.
1998: O'Connell P; Pekkel V; Fuqua S A; Osborne C K; Clark G M; Allred D C
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci.
Journal of the National Cancer Institute 1998;90(9):697-703.
1998: Osborne C K; Elledge R M; Brown P H; Hilsenbeck S G
BRCA1 in clinical breast cancer.
Breast disease 1998;10(1-2):77-88.
1998: Berardo M D; Elledge R M; de Moor C; Clark G M; Osborne C K; Allred D C
bcl-2 and apoptosis in lymph node positive breast carcinoma.
Cancer 1998;82(7):1296-302.
1998: Taylor C W; Green S; Dalton W S; Martino S; Rector D; Ingle J N; Robert N J; Budd G T; Paradelo J C; Natale R B; Bearden J D; Mailliard J A; Osborne C K
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):994-9.
1998: Lavinsky R M; Jepsen K; Heinzel T; Torchia J; Mullen T M; Schiff R; Del-Rio A L; Ricote M; Ngo S; Gemsch J; Hilsenbeck S G; Osborne C K; Glass C K; Rosenfeld M G; Rose D W
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(6):2920-5.
1998: Elledge R M; Green S; Ciocca D; Pugh R; Allred D C; Clark G M; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne C K
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):7-12.
1998: Osborne C K
Steroid hormone receptors in breast cancer management.
Breast cancer research and treatment 1998;51(3):227-38.
1998: Hilsenbeck S G; Ravdin P M; de Moor C A; Chamness G C; Osborne C K; Clark G M
Time-dependence of hazard ratios for prognostic factors in primary breast cancer.
Breast cancer research and treatment 1998;52(1-3):227-37.
1997: Clark G M; Osborne C K; Levitt D; Wu F; Kim N W
Telomerase activity and survival of patients with node-positive breast cancer.
Journal of the National Cancer Institute 1997;89(24):1874-81.
1997: Clark G M; Allred D C; Hilsenbeck S G; Chamness G C; Osborne C K; Jones D; Lee W H
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
Cancer research 1997;57(24):5505-8.
1997: Johnston S R; Lu B; Dowsett M; Liang X; Kaufmann M; Scott G K; Osborne C K; Benz C C
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
Cancer research 1997;57(17):3723-7.
1997: Russell C A; Green S J; O'Sullivan J; Hynes H E; Budd G T; Congdon J E; Martino S; Osborne C K
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2494-501.
1997: Van den Berg C L; Cox G N; Stroh C A; Hilsenbeck S G; Weng C N; McDermott M J; Pratt D; Osborne C K; Coronado-Heinsohn E B; Yee D
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1108-13.
1997: Elledge R M; Osborne C K
Oestrogen receptors and breast cancer.
BMJ (Clinical research ed.) 1997;314(7098):1843-4.
1997: Makris A; Allred D C; Powles T J; Dowsett M; Fernando I N; Trott P A; Ashley S E; Ormerod M G; Titley J C; Osborne C K
Cytological evaluation of biological prognostic markers from primary breast carcinomas.
Breast cancer research and treatment 1997;44(1):65-74.
1997: Elledge R M; Green S; Howes L; Clark G M; Berardo M; Allred D C; Pugh R; Ciocca D; Ravdin P; O'Sullivan J; Rivkin S; Martino S; Osborne C K
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1916-22.
1997: Makris A; Powles T J; Dowsett M; Osborne C K; Trott P A; Fernando I N; Ashley S E; Ormerod M G; Titley J C; Gregory R K; Allred D C
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(4):593-600.
1997: Grøndahl-Hansen J; Hilsenbeck S G; Christensen I J; Clark G M; Osborne C K; Brünner N
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Breast cancer research and treatment 1997;43(2):153-63.
1996: Albain K S; Green S R; Lichter A S; Hutchins L F; Wood W C; Henderson I C; Ingle J N; O'Sullivan J; Osborne C K; Martino S
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):3009-17.
1996: Osborne C K
Aromatase inhibitors in the treatment of advanced breast cancer. Introduction.
Seminars in oncology 1996;23(4 Suppl 9):1.
1996: Oesterreich S; Hilsenbeck S G; Ciocca D R; Allred D C; Clark G M; Chamness G C; Osborne C K; Fuqua S A
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1199-206.
1996: Osborne C K; Coronado-Heinsohn E
Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).
The cancer journal from Scientific American 1996;2(3):175-80.
1996: Nicholson R I; Gee J M; Bryant S; Francis A B; McClelland R A; Knowlden J; Wakeling A E; Osborne C K
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.
Annals of the New York Academy of Sciences 1996;784():325-35.
1996: Gelber R D; Cole B F; Goldhirsch A; Rose C; Fisher B; Osborne C K; Boccardo F; Gray R; Gordon N H; Bengtsson N O; Sevelda P
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
Lancet 1996;347(9008):1066-71.
1996: Brown R W; Allred C D; Clark G M; Osborne C K; Hilsenbeck S G
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):585-92.
1996: Rivkin S E; Green S; O'Sullivan J; Cruz A B; Abeloff M D; Jewell W R; Costanzi J J; Farrar W B; Osborne C K
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):46-51.
1995: Chen Y; Chen C F; Riley D J; Allred D C; Chen P L; Von Hoff D; Osborne C K; Lee W H
Aberrant subcellular localization of BRCA1 in breast cancer.
Science (New York, N.Y.) 1995;270(5237):789-91.
1995: Isola J J; Kallioniemi O P; Chu L W; Fuqua S A; Hilsenbeck S G; Osborne C K; Waldman F M
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer.
The American journal of pathology 1995;147(4):905-11.
1995: Katzenellenbogen J A; Coleman R E; Hawkins R A; Krohn K A; Larson S M; Mendelsohn J; Osborne C K; Piwnica-Worms D; Reba R C; Siegel B A
Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(8):921-32.
1995: Elledge R M; Gray R; Mansour E; Yu Y; Clark G M; Ravdin P; Osborne C K; Gilchrist K; Davidson N E; Robert N
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.
Journal of the National Cancer Institute 1995;87(16):1254-6.
1995: Osborne C K; Coronado-Heinsohn E B; Hilsenbeck S G; McCue B L; Wakeling A E; McClelland R A; Manning D L; Nicholson R I
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Journal of the National Cancer Institute 1995;87(10):746-50.
1995: Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne C K; Clark G M; Danø K; Grøndahl-Hansen J
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Breast cancer research and treatment 1995;33(3):199-207.
1994: Reddy K B; Yee D; Hilsenbeck S G; Coffey R J; Osborne C K
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(12):1275-82.
1994: Rivkin S E; Green S; Metch B; Cruz A B; Abeloff M D; Jewell W R; Costanzi J J; Farrar W B; Minton J P; Osborne C K
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2078-85.
1994: Fabian C J; Kimler B F; McKittrick R; Park C H; Lin F; Krishnan L; Jewell W R; Osborne C K; Martino S; Hutchins L F
Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study.
Cancer research 1994;54(20):5357-62.
1994: Osborne C K
Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee.
Cancer 1994;74(3 Suppl):1135-8.
1994: Elledge R M; Clark G M; Chamness G C; Osborne C K
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
Journal of the National Cancer Institute 1994;86(9):705-12.
1994: Margolin K A; Green S; Osborne K; Doroshow J H; Akman S A; Leong L A; Morgan R J; Raschko J W; Somlo G; Hutchins L
Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer.
American journal of clinical oncology 1994;17(2):175-80.
1994: Ravdin P M; Tandon A K; Allred D C; Clark G M; Fuqua S A; Hilsenbeck S H; Chamness G C; Osborne C K
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):467-74.
1994: Stein D; Wu J; Fuqua S A; Roonprapunt C; Yajnik V; D'Eustachio P; Moskow J J; Buchberg A M; Osborne C K; Margolis B
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.
The EMBO journal 1994;13(6):1331-40.
1994: Osborne C K; Sunderland M C; Neidhart J A; Ravdin P M; Abeloff M D
Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(1):43-7.
1994: Osborne C K; Jarman M; McCague R; Coronado E B; Hilsenbeck S G; Wakeling A E
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.
Cancer chemotherapy and pharmacology 1994;34(2):89-95.
1994: Atiba J O; Green S J; Hynes H E; Osborne C K; Miller T P; Davidner M
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1994;12(2):129-32.
1994: LeMaistre C F; Meneghetti C; Howes L; Osborne C K
Targeting the EGF receptor in breast cancer treatment.
Breast cancer research and treatment 1994;32(1):97-103.
1994: Fuqua S A; Oesterreich S; Hilsenbeck S G; Von Hoff D D; Eckardt J; Osborne C K
Heat shock proteins and drug resistance.
Breast cancer research and treatment 1994;32(1):67-71.
1994: O'Connell P; Pekkel V; Fuqua S; Osborne C K; Allred D C
Molecular genetic studies of early breast cancer evolution.
Breast cancer research and treatment 1994;32(1):5-12.
1994: Osborne C K; Fuqua S A
Mechanisms of tamoxifen resistance.
Breast cancer research and treatment 1994;32(1):49-55.
1994: Allred D C; O'Connell P; Fuqua S A; Osborne C K
Immunohistochemical studies of early breast cancer evolution.
Breast cancer research and treatment 1994;32(1):13-8.
1994: Clark G M; Hilsenbeck S G; Ravdin P M; De Laurentiis M; Osborne C K
Prognostic factors: rationale and methods of analysis and integration.
Breast cancer research and treatment 1994;32(1):105-12.
1994: Osborne C K; Chamness G C
Translational research in the San Antonio breast cancer SPORE.
Breast cancer research and treatment 1994;32(1):1-4.
1993: Osborne C K
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism.
The Journal of steroid biochemistry and molecular biology 1993;47(1-6):83-9.
1993: Oesterreich S; Weng C N; Qiu M; Hilsenbeck S G; Osborne C K; Fuqua S A
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines.
Cancer research 1993;53(19):4443-8.
1993: Hayden K A; Moinpour C M; Metch B; Feigl P; O'Bryan R M; Green S; Osborne C K
Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial.
Oncology nursing forum 1993;20(9):1415-9.
1993: Rivkin S E; Green S; Metch B; Jewell W R; Costanzi J J; Altman S J; Minton J P; O'Bryan R M; Osborne C K
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(9):1710-6.
1993: Wiebe V J; Osborne C K; Fuqua S A; DeGregorio M W
Tamoxifen resistance in breast cancer.
Critical reviews in oncology/hematology 1993;14(3):173-88.
1993: Allred D C; Clark G M; Elledge R; Fuqua S A; Brown R W; Chamness G C; Osborne C K; McGuire W L
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
Journal of the National Cancer Institute 1993;85(3):200-6.
1993: Encarnación C A; Ciocca D R; McGuire W L; Clark G M; Fuqua S A; Osborne C K
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
Breast cancer research and treatment 1993;26(3):237-46.
1992: Allred D C; Clark G M; Molina R; Tandon A K; Schnitt S J; Gilchrist K W; Osborne C K; Tormey D C; McGuire W L
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Human pathology 1992;23(9):974-9.
1992: Reddy K B; Mangold G L; Tandon A K; Yoneda T; Mundy G R; Zilberstein A; Osborne C K
Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
Cancer research 1992;52(13):3636-41.
1992: Wiebe V J; Osborne C K; McGuire W L; DeGregorio M W
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(6):990-4.
1992: Elledge R M; McGuire W L; Osborne C K
Prognostic factors in breast cancer.
Seminars in oncology 1992;19(3):244-53.
1992: Osborne C K
Prognostic factors for breast cancer: have they met their promise?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):679-82.
1992: Allred D C; Clark G M; Tandon A K; Molina R; Tormey D C; Osborne C K; Gilchrist K W; Mansour E G; Abeloff M; Eudey L
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):599-605.
1992: Clark G M; Mathieu M C; Owens M A; Dressler L G; Eudey L; Tormey D C; Osborne C K; Gilchrist K W; Mansour E G; Abeloff M D
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):428-32.
1992: Osborne C K; Wiebe V J; McGuire W L; Ciocca D R; DeGregorio M W
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):304-10.
1992: Benz C C; Scott G K; Sarup J C; Johnson R M; Tripathy D; Coronado E; Shepard H M; Osborne C K
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.
Breast cancer research and treatment 1992;24(2):85-95.
1992: Mansour E G; Eudey L; Tormey D C; Shatila A H; Osborne C K; Gilchrist K W; Cooper M R; Falkson G
Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Journal of the National Cancer Institute. Monographs 1992;(11):97-104.
1992: Dressler L G; Eudey L; Gray R; Tormey D C; McGuire W L; Gilchrist K W; Clark G M; Osborne C K; Mansour E G; Abeloff M D
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).
Journal of the National Cancer Institute. Monographs 1992;(11):167-72.
1992: Osborne C K; Blumenstein B A; Crawford E D; Weiss G R; Bukowski R M; Larrimer N R
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):477-8.
1992: Albain K S; Green S; LeBlanc M; Rivkin S; O'Sullivan J; Osborne C K
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Breast cancer research and treatment 1992;22(3):273-84.
1992: Osborne C K
Polypeptide growth factors: their potential value in the management of breast cancer patients.
Cancer treatment and research 1992;60():315-29.
1991: Osborne C K
Hematopoietic growth factors in breast cancer--overview.
Breast cancer research and treatment 1991;20 Suppl():S1-2.
1991: Osborne C K
Dose intensity as a therapeutic strategy in breast cancer.
Breast cancer research and treatment 1991;20 Suppl():S11-4.
1991: Osborne C K; Coronado E; Allred D C; Wiebe V; DeGregorio M
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.
Journal of the National Cancer Institute 1991;83(20):1477-82.
1991: Budd G T; Green S; Baker L H; Hersh E P; Weick J K; Osborne C K
A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer.
Cancer 1991;68(8):1694-5.
1991: Cowan J D; Neidhart J; McClure S; Coltman C A; Gumbart C; Martino S; Hutchins L F; Stephens R L; Vaughan C B; Osborne C K
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1991;83(15):1077-84.
1991: Sunderland M C; Osborne C K
Tamoxifen in premenopausal patients with metastatic breast cancer: a review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1283-97.
1991: Reddy K B; Yee D; Osborne C K
Rapid identification of transfected plasmid expression vectors in cells by PCR.
BioTechniques 1991;10(4):481-2, 484.
1991: Von Hoff D D; Green S J; Neidhart J A; Fabian C; Budd T; Boyd J F; Osborne C K
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1991;9(1):87-8.
1991: Arteaga C L; Osborne C K
Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells.
Cancer treatment and research 1991;53():289-304.
1990: Osborne C K; Clemmons D R; Arteaga C L
Regulation of breast cancer growth by insulin-like growth factors.
The Journal of steroid biochemistry and molecular biology 1990;37(6):805-9.
1990: Clemmons D R; Camacho-Hubner C; Coronado E; Osborne C K
Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status.
Endocrinology 1990;127(6):2679-86.
1990: Osborne C K; Blumenstein B; Crawford E D; Coltman C A; Smith A Y; Lambuth B W; Chapman R A
Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1675-82.
1990: Osborne C K; Arteaga C L
Autocrine and paracrine growth regulation of breast cancer: clinical implications.
Breast cancer research and treatment 1990;15(1):3-11.
1989: Merkel D E; Osborne C K
Prognostic factors in breast cancer.
Hematology/oncology clinics of North America 1989;3(4):641-52.
1989: Osborne C K; Coronado E B; Kitten L J; Arteaga C I; Fuqua S A; Ramasharma K; Marshall M; Li C H
Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor.
Molecular endocrinology (Baltimore, Md.) 1989;3(11):1701-9.
1989: Arteaga C L; Kitten L J; Coronado E B; Jacobs S; Kull F C; Allred D C; Osborne C K
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.
The Journal of clinical investigation 1989;84(5):1418-23.
1989: Arteaga C L; Osborne C K
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.
Cancer research 1989;49(22):6237-41.
1989: McGuire W L; Johnson P A; Muss H B; Osborne C K
Megestrol acetate in breast cancer--a panel discussion.
Breast cancer research and treatment 1989;14(1):33-8.
1989: Osborne C K
DNA flow cytometry in early breast cancer: a step in the right direction.
Journal of the National Cancer Institute 1989;81(18):1344-5.
1989: Rivkin S E; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi J J; Hoogstraten B; Athens J; Maloney T; Osborne C K
Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(9):1229-38.
1989: Liu E; Santos G; Lee W M; Osborne C K; Benz C C
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells.
Oncogene 1989;4(8):979-84.
1989: Osborne C K; Craig J B; Klein K; Crawford E D; Turner J
Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer.
Investigational new drugs 1989;7(2-3):243-5.
1989: Osborne C K; Kitten L; Arteaga C L
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(6):710-7.
1989: McGuire W L; Abeloff M D; Fisher B; Glick J H; Henderson I C; Osborne C K
Adjuvant therapy in node-negative breast cancer. A panel discussion.
Breast cancer research and treatment 1989;13(2):97-115.
1989: Mansour E G; Gray R; Shatila A H; Osborne C K; Tormey D C; Gilchrist K W; Cooper M R; Falkson G
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
The New England journal of medicine 1989;320(8):485-90.
1989: Merkel D E; Osborne C K
Adjuvant treatment of node-negative breast cancer.
Texas medicine 1989;85(1):32-6.
1989: Dorr R T; Liddil J D; Von Hoff D D; Soble M; Osborne C K
Antitumor activity and murine pharmacokinetics of parenteral acronycine.
Cancer research 1989;49(2):340-4.
1989: McGuire W L; Foley K M; Levy M H; Osborne C K
Pain control in breast cancer. A panel discussion.
Breast cancer research and treatment 1989;13(1):5-15.
1989: DeGregorio M W; Coronado E; Osborne C K
Tumor and serum tamoxifen concentrations in the athymic nude mouse.
Cancer chemotherapy and pharmacology 1989;23(2):68-70.
1989: Osborne C K
Cell proliferative indices and DNA content as prognostic factors in primary breast cancer.
Hormone research 1989;32 Suppl 1():238-41.
1989: Robert N J; Dalton W S; Osborne C K; Abeloff M
Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex.
Hormone research 1989;32 Suppl 1():221-2.
1988: Arteaga C L; Coronado E; Osborne C K
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer.
Molecular endocrinology (Baltimore, Md.) 1988;2(11):1064-9.
1988: McGuire W L; Dickson R B; Osborne C K; Salomon D
The role of growth factors in breast cancer. A panel discussion.
Breast cancer research and treatment 1988;12(2):159-66.
1988: Arteaga C L; Hanauske A R; Clark G M; Osborne C K; Hazarika P; Pardue R L; Tio F; Von Hoff D D
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.
Cancer research 1988;48(17):5023-8.
1988: Osborne C K; Ross C R; Coronado E B; Fuqua S A; Kitten L J
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model.
Breast cancer research and treatment 1988;11(3):211-9.
1988: Arteaga C L; Tandon A K; Von Hoff D D; Osborne C K
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
Cancer research 1988;48(14):3898-904.
1988: Osborne C K
Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer.
Cancer treatment and research 1988;39():111-29.
1987: Brünner N; Osborne C K; Spang-Thomsen M
Endocrine therapy of human breast cancer grown in nude mice.
Breast cancer research and treatment 1987;10(3):229-42.
1987: Brown G R; Askew R E; Gallager H S; Hortobagyi G N; Montague E D; Neff L E; Osborne C K; Race G J; Salem R J; Townsend C M
Breast cancer. Breast Oncology Workgroup, Legislative Task Force on Cancer in Texas.
Texas medicine 1987;83(9 Pt 2):81-96.
1987: Osborne C K; Coronado E B; Robinson J P
Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy.
European journal of cancer & clinical oncology 1987;23(8):1189-96.
1987: Hanauske A R; Osborne C K; Chamness G C; Clark G M; Forseth B J; Buchok J B; Arteaga C L; Von Hoff D D
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents.
European journal of cancer & clinical oncology 1987;23(5):545-51.
1987: Clark G M; Sledge G W; Osborne C K; McGuire W L
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(1):55-61.
1987: DeGregorio M W; Wilbur B J; Coronado E; Osborne C K
Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration.
Cancer chemotherapy and pharmacology 1987;20(4):316-8.
1987: McGuire W L; Lippman M E; Osborne C K; Thompson E B
Resistance to endocrine therapy. A panel discussion.
Breast cancer research and treatment 1987;9(3):165-73.
1987: Osborne C K; Hobbs K; Trent J M
Biological differences among MCF-7 human breast cancer cell lines from different laboratories.
Breast cancer research and treatment 1987;9(2):111-21.
1986: Osborne C K; Coltman C A
Adjuvant chemotherapy.
CA: a cancer journal for clinicians 1986;36(1):59-60.
1986: Graham K A; Trent J M; Osborne C K; McGrath C M; Minden M D; Buick R N
The use of restriction fragment polymorphisms to identify the cell line MCF-7.
Breast cancer research and treatment 1986;8(1):29-34.
1986: Osborne C K; Rivkin S E; McDivitt R W; Green S; Stephens R L; Costanzi J J; O'Bryan R
Adjuvant therapy of breast cancer: Southwest Oncology Group studies.
NCI monographs : a publication of the National Cancer Institute 1986;(1):71-4.
1985: Rivkin S E; Knight W A; McDivitt R; Cruz T; Foulkes M; Osborne C K; Fabian C J; Costanzi J J
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Journal of steroid biochemistry 1985;23(6B):1151-4.
1985: Rivkin S E; Knight W A; McDivitt R; Cruz T; Foulkes M; Osborne C K; Fabian C J; Costanzi J J
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
World journal of surgery 1985;9(5):723-7.
1985: Rivkin S E; Glucksberg H; Foulkes M; Osborne C K; Tranum W; Gad-el-Mawla N; Constanzi J
Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM.
World journal of surgery 1985;9(5):719-22.
1985: Osborne C K
Heterogeneity in hormone receptor status in primary and metastatic breast cancer.
Seminars in oncology 1985;12(3):317-26.
1985: Osborne C K; Hobbs K; Clark G M
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Cancer research 1985;45(2):584-90.
1985: Cowan J D; Osborne C K; Neidhart J A; Von Hoff D D; Constanzi J J; Vaughn C B
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Investigational new drugs 1985;3(2):149-52.
1985: Osborne C K; Von Hoff D D; Mullins K
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
Breast cancer research and treatment 1985;6(3):229-35.
1984: Coltman C A; Osborne C K
Bisantrene, biological and clinical effects.
Cancer treatment reviews 1984;11(4):285-8.
1984: Osborne C K
Hormone receptors in the management of breast cancer.
Texas medicine 1984;80(11):30-2.
1984: Clark G M; Osborne C K; McGuire W L
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(10):1102-9.
1984: Gross G E; Boldt D H; Osborne C K
Perturbation by insulin of human breast cancer cell cycle kinetics.
Cancer research 1984;44(8):3570-5.
1984: Osborne C K; Boldt D H; Estrada P
Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
Cancer research 1984;44(4):1433-9.
1984: Osborne C K; Von Hoff D D; Cowan J D; Sandbach J
Bisantrene, an active drug in patients with advanced breast cancer.
Cancer treatment reports 1984;68(2):357-60.
1983: Osborne C K; Drelichman A; Von Hoff D D; Crawford E D
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Cancer treatment reports 1983;67(12):1133-5.
1983: Ibbotson K J; D'Souza S M; Ng K W; Osborne C K; Niall M; Martin T J; Mundy G R
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy.
Science (New York, N.Y.) 1983;221(4617):1292-4.
1983: Osborne C K; Boldt D H; Clark G M; Trent J M
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.
Cancer research 1983;43(8):3583-5.
1983: Garvin A J; Simon R M; Osborne C K; Merrill J; Young R C; Berard C W
An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute.
Cancer 1983;52(3):393-8.
1983: Hull D F; Clark G M; Osborne C K; Chamness G C; Knight W A; McGuire W L
Multiple estrogen receptor assays in human breast cancer.
Cancer research 1983;43(1):413-6.
1983: Myers J W; Von Hoff D D; Kuhn J G; Osborne C K; Sandbach J F; Pocelinko R
Anaphylactoid reactions associated with bisantrene infusions.
Investigational new drugs 1983;1(1):85-8.
1983: Monaco M E; Osborne C K; Bronzert T J; Kidwell W R; Lippman M E
Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells.
Breast cancer research and treatment 1983;3(3):279-85.
1982: McGuire W L; Osborne C K; Clark G M; Knight W A
Steroid hormone receptors and carcinoma of the breast.
The American journal of physiology 1982;243(2):E99-102.
1982: Hubbard S M; Chabner B A; DeVita V T; Simon R; Berard C W; Jones R B; Garvin A J; Canellos G P; Osborne C K; Young R C
Histologic progression in non-Hodgkin's lymphoma.
Blood 1982;59(2):258-64.
1982: Elson D L; Osborne C K; Livingston R B; Von Hoff D D
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition.
Stem cells 1982;2(1):34-44.
1982: Suarez A J; Lamm D L; Radwin H M; Sarosdy M; Clark G; Osborne C K
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer.
Cancer chemotherapy and pharmacology 1982;8(3):261-5.
1981: Osborne C K; Hamilton B; Nover M; Ziegler J
Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells.
The Journal of clinical investigation 1981;67(4):943-51.
1981: Von Hoff D D; Sandbach J; Osborne C K; Metelmann C; Clark G M; O'Brien M
Potential and problems with growth of breast cancer in a human tumor cloning system.
Breast cancer research and treatment 1981;1(2):141-8.
1981: Knight W A; Clark G M; Osborne C K; McGuire W L
Adjuvant therapy for stage II, estrogen receptor negative breast cancer.
Breast cancer research and treatment 1981;1(2):131-4.
1981: Osborne C K
Combined chemo-hormonal therapy in breast cancer: a hypothesis.
Breast cancer research and treatment 1981;1(2):121-3.
1981: Fisher E R; Osborne C K; McGuire W L; Redmond C; Knight W A; Fisher B; Bannayan G; Walder A; Gregory E J; Jacobsen A; Queen D M; Bennett D E; Ford H C
Correlation of primary breast cancer histopathology and estrogen receptor content.
Breast cancer research and treatment 1981;1(1):37-41.
1981: Osborne C K; Fisher E; Redmond C; Knight W A; Yochmowitz M G; McGuire W L
Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis.
Advances in experimental medicine and biology 1981;138():377-85.
1980: Osborne C K; Yochmowitz M G; Knight W A; McGuire W L
The value of estrogen and progesterone receptors in the treatment of breast cancer.
Cancer 1980;46(12 Suppl):2884-8.
1980: Osborne C K; Knight W A; Yochmowitz M G; McGuire W L
Modern approaches to the treatment of breast cancer.
Blood 1980;56(5):745-52.
1980: Knight W A; Osborne C K; Yochmowitz M G; McGuire W L
Steroid hormone receptors in the management of human breast cancer.
Annals of clinical research 1980;12(5):202-7.
1980: Osborne C K; Norton L; Young R C; Garvin A J; Simon R M; Berard C W; Hubbard S; DeVita V T
Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival.
Blood 1980;56(1):98-103.
1980: Osborne C K; Hamilton B; Titus G; Livingston R B
Epidermal growth factor stimulation of human breast cancer cells in culture.
Cancer research 1980;40(7):2361-6.
1980: Knight W A; Osborne C K; McGuire W L
Hormone receptors in primary and advanced breast cancer.
Clinics in endocrinology and metabolism 1980;9(2):361-8.
1979: Gaskill S P; McGuire W L; Osborne C K; Stern M P
Breast cancer mortality and diet in the United States.
Cancer research 1979;39(9):3628-37.
1979: Osborne C K; Monaco M E; Kahn C R; Huff K; Bronzert D; Lippman M E
Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture.
Cancer research 1979;39(7 Pt 1):2422-8.
1979: Osborne C K; McGuire W L
Therapy for cancer of the breast. Current status of steroid hormone receptors.
The Western journal of medicine 1979;130(5):401-7.
1979: Osborne C K; McGuire W L
The use of steroïd hormone receptors in the treatment of human breast cancer: a review.
Bulletin du cancer 1979;66(3):203-9.
1978: Osborne C K; McGuire W L
Current use of steroid hormone receptor assays in the treatment of breast cancer.
The Surgical clinics of North America 1978;58(4):777-88.
1978: Osborne C K; Monaco M E; Lippman M E; Kahn C R
Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture.
Cancer research 1978;38(1):94-102.
1977: Monaco M E; Osborne C K; Lippman M E
Insulin stimulation of fatty acid synthesis in human breast cancer cells.
Journal of the National Cancer Institute 1977;58(6):1591-3.
1977: Lippman M E; Osborne C K; Knazek R; Young N
In vitro model systems for the study of hormone-dependent human breast cancer.
The New England journal of medicine 1977;296(3):154-9.
1976: Osborne C K; Bolan G; Monaco M E; Lippman M E
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin.
Proceedings of the National Academy of Sciences of the United States of America 1976;73(12):4536-40.
1976: Woolley P V; Osborne C K; Levi J A; Wiernik P H; Canellos G P
Extranodal presentation of non-Hodgkin's lymphomas in the testis.
Cancer 1976;38(2):1026-35.
1973: Osborne C K; Carolla R; Jefferson D; Mengel C E
Effect of methemoglobin on in vivo RBC lipid peroxidation.
Aerospace medicine 1973;44(1):63-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Kent Osborne

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Physiology

Living Beings

Anatomy

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Kent Osborne (preview)

All Publications